Ozempic: Hijacking Of Diabetes Drug From Its Created Use

By Andre ‘M. Johnson

According to a recent study published in Lucent, the number of people living with diabetes worldwide is on pace to more than double in the next three decades. This increase will bring the total of worldwide diabetic patients to a staggering 1.3 billion by 2025, making diabetes one of the top 10 leading causes of death and disability, in the world.

On December 5th of 2017, a little-known drug hit the market to help millions of people suffering with diabetes. The drug was called Ozempic. Ozempic was created to lower blood sugar by stimulating the pancreas to produce more insulin and has shown continual success in patients with lowering their A1-C.

The introduction of medications such as Ozempic and Wegovy has changed the game for millions of people worldwide who have been struggling with diabetes. It was a once weekly auto injector that would allow patients to maintain their sugar levels and create a healthier way of life. One of its known side effects, however, was dramatic weight loss.

In early 2022, Ozempic rose to fame when celebrities who do not suffer from diabetes began publicizing the drug’s ability to assist in fast acting weight loss. It quickly went from a lifesaving medication for diabetics to the celebrity go-to for shedding unwanted pounds.

Valentine Paterson of Brooklyn, New York thought he had found a solution to his endless battle with obesity and diabetes when he was prescribed Ozempic. The effects were almost immediate and life altering. “I weighed more than 365 pounds and after being hospitalized for heart failure, my doctor recommended I take Ozempic,” said Paterson a 52-year-old Uber driver.

“Within four months of taking the drug, I lost 65 pounds, and my doctor reduced my other medications from nine to four. It changed my life. But then I could not get my prescription filled. I looked for months; it was a nightmare. All the work and progress I was making was slipping away, all because I was unable to pay out of pocket.”

The reason Mr. Paterson could not get his prescription filled is because Mr. Paterson’s local pharmacy, like many others nationwide, was no longer able to obtain the blockbuster medication.

Ozempic and Wegovy created a nationwide shortage of medication by those willing to pay the exorbitant out-of-pocket costs getting first cracks at the available supply. So, while pharmacies in lower income neighborhoods could not stock their shelves, pharmacies on Manhattan’s Upper Eastside had a twelve-month supply of the miracle drug readily available to those able to pay $1,400 per prescription. Given this void, the question was raised as to whether anyone or anything could help.

Enter the compounding pharmacy. According to the FDA, compounding pharmacies are authorized to produce exact drugs in times of a national shortage by making generic versions of those medications to assist all those in need. When a medicine is not on the national shortage list, compounding pharmacies are only authorized to make alternate forms of the prescribed drug.

Ozempic has been on both the worldwide and U.S. shortage list since April of 2022. However, what happens when Big Pharma doesn’t want to let compounding pharmacies earn money they feel belongs to them even during a shortage?

“Lifeline Pharmacy” is a small compounding pharmacy run by Dr. Aisha Johnson in the heart of south Los Angeles. For years, this pharmacy has served as a beacon of hope, providing personalized care and essential medications to the predominantly Black and Latino residents. Among the most critical medications Dr. Johnson compounds is semaglutide, the active ingredient in Ozempic and Wegovy.

According to the US Department of Health and Human Services, Black adults are nearly twice as likely as white adults to develop type 2 diabetes. This racial disparity has been rising over the last 30 years creating a disproportionate need for these life altering medications in communities of color. Despite the FDA’s approval for compounding pharmacies to produce semaglutide, Novo Nordisk has targeted these providers in order to protect their profits and eliminate the competition.

The impact of Big Pharma’s campaign is being felt in communities from Brooklyn, NY to Los Angeles, CA. The misinformation spread by Novo Nordisk, stating that compounded versions of semagludies are unsafe and potentially life threating has created fear and uncertainty in those using compounded versions of the popular medication. 

Intensifying the problem, legislative proposals influenced by pharmaceutical lobbyists threatened to impose restrictions that would make it nearly impossible for small pharmacies to continue compounding semaglutide.

For communities of color, this means losing a critical source of affordable and accessible medication.

The popularity of these drugs has made it difficult for average Americans to afford or find these medications. These are not just weight loss medications; they are tools for survival for many diabetic patients. Many patients have been forced to accept lower doses of these drugs to maintain any benefits even though most experience little to no progress with the reduced dosage.